Saturday 17 October 2026 Export DMAC’s income statement to Excel — free account

DiaMedica Therapeutics, Inc.

In the quarter to June 2026, EPS fell 5.56%, free cash flow fell 6.75% and total debt fell 90.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

7.60 0.44 −5.47%

Follow DMAC

Alert me

Market cap: $433.6M
P/E: 0.0×
Fwd P/E: −2.8×
Dividend yield: —
F-score: n/a
Altman Z: 6.68
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 7.63

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 43.30%

Capital & Financial Ratios $m

Market Cap 433.56

Revenue —

Net Income (37.54)

Free Cash Flow (31.54)

Net Debt (43.50)

Current Ratio 6.72

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (2.80)

P/S ratio 0.00

P/B ratio 10.68

Past 5Y EPS Growth —

This Y EPS Growth (10.00%)

Next Y EPS Growth 2.92%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth (9.82%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 81.57%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	53	44	60	44
Receivables	0	0	0	0
Inventory	—	—	—	—
Other	—	—	—	—
	54	45	61	44

	2023	2024	2025	Q'26
Payables	1	1	1	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	3	5	5	7

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	16.62%	20.80%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(8)	—	—	—
’25	(7)	(8)	(7)	(8)	(29)
’24	(7)	(5)	(4)	(6)	(22)
’23	(5)	(5)	(5)	(4)	(19)
’22	(4)	(2)	(2)	(3)	(12)
’21	(4)	(2)	(3)	(3)	(12)
’20	(3)	(1)	(2)	(3)	(9)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(8)	—	—	—
’25	(7)	(8)	(7)	(8)	(29)
’24	(7)	(5)	(4)	(6)	(22)
’23	(5)	(5)	(5)	(4)	(19)
’22	(4)	(3)	(2)	(3)	(12)
’21	(4)	(2)	(3)	(3)	(12)
’20	(3)	(1)	(2)	(3)	(9)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.19)	(0.19)	—	—	—
’25	(0.18)	(0.18)	(0.17)	(0.17)	(0.70)
’24	(0.14)	(0.13)	(0.15)	(0.18)	(0.60)
’23	(0.20)	(0.16)	(0.12)	(0.14)	(0.60)
’22	(0.13)	(0.13)	(0.12)	(0.14)	(0.52)
’21	(0.19)	(0.17)	(0.18)	(0.10)	(0.65)
’20	(0.19)	(0.17)	(0.19)	(0.23)	(0.78)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1.90	2.19	2.46	1.70	1.87	3.00	1.12	1.27	2.14	3.19	Analyst estimates 2026–2028 Powerpack
	High	5.25	6.90	13.77	5.93	10.43	10.88	3.94	4.75	6.41	10.42
People
People	Employees	7	9	9	9	11	15	16	19	28	35
	Revenue/emp, $m	0.00	0.00	0.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	1	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	100.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(2)	(4)	(6)	(11)	(12)	(14)	(14)	(19)	(24)	(33)
	EBT margin, %	0.00	0.00	(1,130.80)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(2)	(4)	(6)	(11)	(12)	(14)	(14)	(19)	(24)	(33)
	Depreciation	0	0	0	0	0	0	0	(1)	(1)	(1)
Per share, $
Per share, $	Revenue	0.00	0.00	0.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(0.47)	(0.68)	(0.74)	(0.89)	(0.78)	(0.65)	(0.52)	(0.60)	(0.60)	(0.70)
	Cash flow	(0.64)	(0.66)	(0.74)	(0.76)	(0.59)	(0.59)	(0.44)	(0.58)	(0.55)	(0.62)
	Capex	0.00	0.00	(0.01)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(0.64)	(0.66)	(0.74)	(0.76)	(0.59)	(0.59)	(0.44)	(0.58)	(0.55)	(0.62)
	Book value	0.26	0.13	2.20	0.64	1.66	2.12	1.20	1.57	1.01	1.19
	Shares, m	5	6	8	12	16	21	26	33	40	47
Valuation, ×
Valuation, ×	P/E	—	—	0.00	—	—	—	—	—	—	—
	P/S	—	—	0.00	—	—	—	—	—	—	—
	P/B	—	—	1.32	—	—	—	—	—	—	—
	EV/Sales	—	—	0.00	—	—	—	—	—	—	—
	EV/FCF	—	—	(1.00)	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(3)	(4)	(6)	(9)	(9)	(12)	(12)	(19)	(22)	(29)
	Capex	0	0	0	0	0	0	0	0	0	0
	Free cash flow	(3)	(4)	(6)	(9)	(9)	(12)	(12)	(19)	(22)	(29)
Balance, $m
Balance, $m	Working capital	1	0	17	8	26	44	32	51	39	55
	Total debt	0	—	0	0	0	0	0	0	0	0
	Net debt	(2)	(1)	(17)	(8)	(27)	(45)	(33)	(53)	(44)	(60)
	Shareholders’ equity	1	1	17	8	26	44	32	51	41	56
Returns, %
Returns, %	ROA	(212.13)	(231.84)	(56.94)	(77.75)	(66.18)	(36.91)	(34.21)	(43.77)	(48.64)	(60.84)
	ROIC	0.00	0.00	(1,920.74)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(33,683.33)	(416.63)	(64.34)	(86.43)	(73.10)	(38.81)	(36.06)	(46.77)	(53.27)	(67.68)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2018 · latest quarter Sep 2018

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EPRX Eupraxia Pharmaceuticals Inc.	$446.2M	— (loss-making)	—	—	n/m	−56.41% (below 0%: shrinking)	—	0.00%	Compare
MPLT MapLight Therapeutics, Inc.	$445.7M	— (loss-making)	—	—	n/m	−31.91% (below 0%: shrinking)	—	0.00%	Compare
OVID Ovid Therapeutics	$441.4M	— (loss-making)	— (loss-making)	+463.85% (above 0%: growing)	n/m	−268.54% (below 0%: shrinking)	100.00%	(2,141.61%)	Compare
PROK ProKidney Corp.	$439.9M	— (loss-making)	— (loss-making)	−32.13% (below 0%: shrinking)	n/m	−28.03% (below 0%: shrinking)	100.00%	(32,248.67%)	Compare
INDP Indaptus Therapeutics, Inc.	$437.7M	— (loss-making)	—	—	n/m	+52.03% (above 0%: growing)	0.00%	0.00%	Compare
PRTA Prothena Corporation plc	$436.4M	— (loss-making)	188×	−77.15% (below 0%: shrinking)	n/m	+44.64% (above 0%: growing)	100.00%	(2,089.21%)	Compare
DMAC DiaMedica Therapeutics, Inc.	$433.6M	— (loss-making)	— (loss-making)	—	n/m	−6.75% (below 0%: shrinking)	0.00%	0.00%
PRTCY PureTech Health PLC Sponsored ADR	$424.0M	— (loss-making)	— (loss-making)	−44.60% (below 0%: shrinking)	+66.43% (above 0%: growing)	+19.27% (above 0%: growing)	2.83%	0.00%	Compare
CAPR Capricor Therapeutics, Inc.	$422.7M	— (loss-making)	— (loss-making)	−7.92% (below 0%: shrinking)	n/m	−72.88% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$438.8M	—	—	−32.13%	—	−29.97%	100.00%	0.00%

All 614 Biotechnology stocks →

DiaMedica Therapeutics, Inc. (DMAC) key facts

DiaMedica Therapeutics, Inc. (DMAC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, DMAC traded at $7.60, a market capitalization of $433.6 million.
Return on equity was −67.7% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.